SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-235288
Filing Date
2020-08-31
Accepted
2020-08-31 06:08:06
Documents
15
Period of Report
2020-08-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d98794d8k.htm   iXBRL 8-K 53302
2 EX-2.1 d98794dex21.htm EX-2.1 493230
3 EX-99.1 d98794dex991.htm EX-99.1 30903
7 GRAPHIC g98794g0831045546691.jpg GRAPHIC 4487
  Complete submission text file 0001193125-20-235288.txt   841159

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA aimt-20200829.xsd EX-101.SCH 3066
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aimt-20200829_lab.xml EX-101.LAB 18138
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aimt-20200829_pre.xml EX-101.PRE 11405
8 EXTRACTED XBRL INSTANCE DOCUMENT d98794d8k_htm.xml XML 3359
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

IRS No.: 452748244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37519 | Film No.: 201149702
SIC: 2834 Pharmaceutical Preparations